Search
Home
News
Coins2Day 500
Coins2Day Global 500
Coins2Day 500 Europe
Coins2Day China 500
Coins2Day SEA 500
Great Place To Work
Tech
AI
Innovation
Cybersecurity
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Success
Future Of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Analytics
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Home
News
Coins2Day 500
Coins2Day 500
Coins2Day Global 500
Coins2Day 500 Europe
Coins2Day China 500
Coins2Day SEA 500
Great Place To Work
Tech
Tech
AI
Innovation
Cybersecurity
Finance
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Leadership
Success
Future Of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Rankings
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Asia
Europe
Analytics
home
home
Gilead Sciences
Gilead Sciences
Gilead Sciences (GILD) Q2 2025 Earnings Call Transcript
By
Industry Analyst
August 7, 2025
Health
U.S. approves twice-a-year shot to prevent HIV but cuts to public health and foreign aid cloud its prospects
By
Lauran Neergaard
and
The Associated Press
June 19, 2025
Gilead Sciences (GILD) Q1 2025 Earnings Call Transcript
By
Digital Assets Editor
April 24, 2025
Gilead Sciences (GILD) Q4 2024 Earnings Call Transcript
By
Digital Assets Editor
February 11, 2025
Health
In patient with long-term COVID-19, coronavirus mutated to resist antiviral Remdesivir
By
Jason Gale
and
Bloomberg
November 11, 2021
Conferences
Can the pandemic-induced collaboration among health care companies have a real impact on inequality?
By
Trading Desk
April 29, 2021
Conferences
Gilead’s remdesivir is now used to treat half of hospitalized COVID patients
By
Research Team
April 28, 2021
Health
Gilead shares jump on FDA approval of remdesivir
By
Robert Langreth
and
Bloomberg
October 23, 2020
Health
Gilead says remdesivir slashes coronavirus deaths. But it’s complicated
By
Digital Assets Editor
July 10, 2020
Health
Gilead to charge thousands for coronavirus treatment drug that critics say should cost $1
By
Robert Langreth
and
Bloomberg
June 29, 2020
Newsletters
The April stocks rally defied the odds. Here’s what’s driving markets
By
Research Team
April 30, 2020
Magazine
Big Pharma has the chance to come to the world’s rescue
By
Investment Desk
April 20, 2020
Health
Gilead stock surges on report of coronavirus drug patients ‘seeing rapid recoveries’
By
Drew Armstrong
and
Bloomberg
April 16, 2020
Newsletters
Gilead made a remarkable request of the FDA in regard to its coronavirus drug
By
Research Team
March 25, 2020
International
HIV pill fails while flu medication helps in early coronavirus drug trials
By
Jason Gale
and
Bloomberg
March 19, 2020
Most Popular
AI
Elon Musk says that in 10 to 20 years, work will be optional and money will be irrelevant thanks to AI and robotics
By
Blockchain Reporter
Economy
One of the world’s most popular economists on why AI is ‘undoubtedly going to crash’: It’s built off ‘digital...
By
Digital Assets Editor
Big Tech
Nvidia CEO says the company is in a no-win situation amid AI-bubble chatter, leaked meeting reveals
By
Blockchain Reporter